サイトカイン放出症候群治療の世界市場レポート 2025年

サイトカイン放出症候群治療市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR13.4％で23億5,000万米ドルに成長します。予測期間の成長は、自己免疫疾患の有病率の増加、がん治療の罹患率の増加、標的治療の利用可能性の増加、バイオテクノロジーとライフサイエンスへの投資の増加、モノクローナル抗体の使用の増加に起因しています。予測期間における主な動向としては、バイオマーカーに基づく治療の実施、次世代IL-6阻害剤の開発、CAR-T細胞療法の進展、バイオシミラーの採用、モノクローナル抗体療法の進展などが挙げられます。

がん治療の罹患率の増加は、サイトカイン放出症候群（CRS）治療市場の拡大を促進すると予測されています。このようながん治療の増加は、世界のがん罹患率の上昇と、早期発見と幅広い治療選択肢を可能にする診断技術の進歩によって促進されています。さらに、生存率の向上とヘルスケアへのアクセスの向上が、これらの治療に対する需要の増加に寄与しています。CRSの治療には、支持療法、抗サイトカイン治療、症状に対処し、がん治療によって引き起こされる炎症反応を抑えるための継続的モニタリングが含まれます。例えば、国民保健サービス（NHS）は2023年1月、2021年11月から2022年10月の間に32万人以上ががん治療を受けたと報告したが、これは記録上最多であり、以前の数字から8,000人以上増加しています。その結果、がん治療の増加がCRS治療市場の成長を後押ししています。

CRS治療市場の主要企業は、治療の精度を高め、副作用を最小限に抑え、患者の転帰を改善するために、静脈内注入などのドラッグデリバリー技術を進歩させています。点滴は、薬物を迅速かつ正確に血流に送り込むことができるため、即効性のある治療効果が期待できます。例えば、2023年9月、日本の製薬会社である中外製薬株式会社は、輸液用薬剤の製造・販売を開始しました。日本の製薬会社である中外製薬株式会社は、ヒト化抗IL-6レセプターモノクローナル抗体であるアクテムラ（一般名：トシリズマブ）について、様々ながん治療によって誘発されるCRSの治療薬として厚生労働省から承認を取得しました。アクテムラ点滴静注は、80mg、200mg、400mgの用量があり、腫瘍特異的T細胞輸注療法以外のがん治療によるCRSの治療薬として承認されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界サイトカイン放出症候群治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のサイトカイン放出症候群治療市場：成長率分析
• 世界のサイトカイン放出症候群治療市場の実績：規模と成長, 2019-2024
• 世界のサイトカイン放出症候群治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界サイトカイン放出症候群治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のサイトカイン放出症候群治療市場薬剤の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• コルチコステロイド
• モノクローナル抗体
• その他の免疫抑制剤
• 世界のサイトカイン放出症候群治療市場管理局による、実績と予測, 2019-2024, 2024-2029F, 2034F
• 静脈内
• 皮下
• オーラル
• 世界のサイトカイン放出症候群治療市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍治療
• 自己免疫疾患
• その他の用途
• 世界のサイトカイン放出症候群治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• 在宅ケア設定
• 世界のサイトカイン放出症候群治療市場コルチコステロイドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• プレドニゾン
• デキサメタゾン
• メチルプレドニゾロン
• 世界のサイトカイン放出症候群治療市場モノクローナル抗体の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• トシリズマブ（IL-6阻害剤）
• シルツキシマブ（IL-6阻害剤）
• アナキンラ（IL-1受容体拮抗薬）
• 世界のサイトカイン放出症候群治療市場その他の免疫抑制剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヤヌスキナーゼ（JAK）阻害剤
• カルシニューリン阻害剤
• 腫瘍壊死因子（TNF）阻害剤

第7章 地域別・国別分析

• 世界のサイトカイン放出症候群治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のサイトカイン放出症候群治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• サイトカイン放出症候群治療市場：競合情勢
• サイトカイン放出症候群治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bayer AG
• Sanofi S.A.
• Thermo Fisher Scientific Inc.
• Novartis AG
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Gilead Sciences Inc.
• Amgen Inc.
• Regeneron Pharmaceuticals Inc.
• Chugai Pharmaceutical Co. Ltd.
• Incyte Corporation
• Swedish Orphan Biovitrum AB（publ）
• Bio-Techne Corporation
• GenScript Biotech Corporation

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• サイトカイン放出症候群治療市場2029：新たな機会を提供する国
• サイトカイン放出症候群治療市場2029：新たな機会を提供するセグメント
• サイトカイン放出症候群治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Cytokine release syndrome (CRS) treatment involves medical interventions aimed at managing and alleviating the severe inflammatory response caused by cytokine release, which can occur with certain therapies such as CAR-T cell treatments. These treatments work to control symptoms, decrease inflammation, and enhance patient outcomes during intense cytokine reactions.

The primary drug types for managing cytokine release syndrome include corticosteroids, monoclonal antibodies, and other immunosuppressants. Corticosteroids are designed to reduce inflammation by mimicking hormones produced by the adrenal glands that regulate inflammation and the immune system. These drugs can be administered intravenously, subcutaneously, or orally, and are used in the treatment of oncological conditions, autoimmune disorders, and other applications. End users of these treatments include hospitals, specialty clinics, and home care settings.

The cytokine release syndrome treatment market research report is one of a series of new reports from the business research company that provides cytokine release syndrome treatment market statistics, including cytokine release syndrome treatment industry global market size, regional shares, competitors with an cytokine release syndrome treatment market share, detailed cytokine release syndrome treatment market segments, market trends and opportunities, and any further data you may need to thrive in the cytokine release syndrome treatment industry. This cytokine release syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cytokine release syndrome treatment market size has grown rapidly in recent years. It will grow from $1.25 billion in 2024 to $1.42 billion in 2025 at a compound annual growth rate (CAGR) of 13.7%. The growth in the historic period can be attributed to increasing prevalence of cancer, rising adoption of immunotherapy, growth in biopharmaceutical investments, increasing clinical trials, growth in personalized medicine.

The cytokine release syndrome treatment market size is expected to see rapid growth in the next few years. It will grow to $2.35 billion in 2029 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to increasing prevalence of autoimmune disorders, increasing incidence of cancer therapies, increasing availability of targeted therapies, rising investment in biotechnology and life sciences, rising use of monoclonal antibodies. Major trends in the forecast period include implementation of biomarker based therapies, development of next generation IL-6 inhibitors, advancements in CAR-T cell therapy, adoption of biosimilars, advancements in monoclonal antibody therapies.

The growing incidence of cancer treatments is projected to drive the expansion of the cytokine release syndrome (CRS) treatment market. This increase in cancer treatments is fueled by the rising global cancer rates and advancements in diagnostic technologies that allow for earlier detection and a wider range of treatment options. Additionally, better survival rates and greater access to healthcare are contributing to the increased demand for these therapies. Managing CRS involves supportive care, anti-cytokine treatments, and continuous monitoring to address symptoms and reduce the inflammatory response triggered by cancer treatments. For example, the National Health Service (NHS) reported in January 2023 that over 320,000 people received cancer treatment between November 2021 and October 2022, the highest number recorded and an increase of more than 8,000 from previous figures. As a result, the rise in cancer treatments is fueling the growth of the CRS treatment market.

Leading companies in the CRS treatment market are advancing drug delivery technologies, such as intravenous infusion, to enhance treatment precision, minimize side effects, and improve patient outcomes. Intravenous infusion allows for the rapid and accurate delivery of drugs into the bloodstream, ensuring immediate therapeutic effects. For instance, in September 2023, Chugai Pharmaceutical Co. Ltd., a Japanese pharmaceutical company, received approval from Japan's Ministry of Health, Labor, and Welfare for Actemra (tocilizumab), a humanized anti-IL-6 receptor monoclonal antibody, for the treatment of CRS induced by various cancer therapies. Actemra Intravenous Infusion, available in 80 mg, 200 mg, and 400 mg doses, has been approved for treating CRS caused by cancer therapies beyond tumor-specific T-cell infusion therapy.

In March 2024, Merck & Co. Inc., a US-based pharmaceutical firm, acquired Harpoon Therapeutics for $680 million. This acquisition aims to expand Merck's cancer therapy portfolio, with a particular focus on T-cell engagers. This includes Harpoon's leading candidate, MK-6070 (formerly HPN328), which targets delta-like ligand 3 (DLL3), a protein linked to small cell lung cancer (SCLC) and neuroendocrine tumors. Harpoon Therapeutics, a US-based clinical-stage immunotherapy company, specializes in TriTAC-XR, a treatment designed for CRS.

Major companies operating in the cytokine release syndrome treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Thermo Fisher Scientific Inc., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Chugai Pharmaceutical Co. Ltd., Incyte Corporation, Swedish Orphan Biovitrum AB (publ), Bio-Techne Corporation, GenScript Biotech Corporation, Abcam plc, Applied Biological Materials Inc., Poolbeg Pharma, arigo Biolaboratories Corp., CytoAgents Inc, bluebird bio Inc.

North America was the largest region in the cytokine release syndrome treatment market in 2024. The regions covered in the cytokine release syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cytokine release syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cytokine release syndrome treatment market consists of revenues earned by entities by providing services such as diagnostic services, clinical trials, hospital and medical services for treatment administration, and regulatory and compliance services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cytokine release syndrome treatment also includes sales of supportive medications such as analgesics and antipyretics, anti-cytokine therapies, and diagnostic tools. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cytokine Release Syndrome Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cytokine release syndrome treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cytokine release syndrome treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cytokine release syndrome treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Corticosteroids; Monoclonal Antibodies; Other Immunosuppressants
• 2) By Administration: Intravenous; Subcutaneous; Oral
• 3) By Application: Oncological Treatments; Autoimmune Disorders; Other Applications
• 4) By End User: Hospitals; Specialty Clinics; Home Care Settings
• Subsegments:
• 1) Corticosteroids: Prednisone; Dexamethasone; Methylprednisolone
• 2) Monoclonal Antibodies: Tocilizumab (IL-6 Inhibitor); Siltuximab (IL-6 Inhibitor); Anakinra (IL-1 Receptor Antagonist)
• 3) Other Immunosuppressants: Janus Kinase (JAK) Inhibitors; Calcineurin Inhibitors; Tumor Necrosis Factor (TNF) Inhibitors
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cytokine Release Syndrome Treatment Market Characteristics

3. Cytokine Release Syndrome Treatment Market Trends And Strategies

4. Cytokine Release Syndrome Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Cytokine Release Syndrome Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Cytokine Release Syndrome Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Cytokine Release Syndrome Treatment Market Growth Rate Analysis
• 5.4. Global Cytokine Release Syndrome Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Cytokine Release Syndrome Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Cytokine Release Syndrome Treatment Total Addressable Market (TAM)

6. Cytokine Release Syndrome Treatment Market Segmentation

• 6.1. Global Cytokine Release Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Monoclonal Antibodies
• Other Immunosuppressants
• 6.2. Global Cytokine Release Syndrome Treatment Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous
• Subcutaneous
• Oral
• 6.3. Global Cytokine Release Syndrome Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncological Treatments
• Autoimmune Disorders
• Other Applications
• 6.4. Global Cytokine Release Syndrome Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Home Care Settings
• 6.5. Global Cytokine Release Syndrome Treatment Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prednisone
• Dexamethasone
• Methylprednisolone
• 6.6. Global Cytokine Release Syndrome Treatment Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tocilizumab (IL-6 Inhibitor)
• Siltuximab (IL-6 Inhibitor)
• Anakinra (IL-1 Receptor Antagonist)
• 6.7. Global Cytokine Release Syndrome Treatment Market, Sub-Segmentation Of Other Immunosuppressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Janus Kinase (JAK) Inhibitors
• Calcineurin Inhibitors
• Tumor Necrosis Factor (TNF) Inhibitors

7. Cytokine Release Syndrome Treatment Market Regional And Country Analysis

• 7.1. Global Cytokine Release Syndrome Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Cytokine Release Syndrome Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cytokine Release Syndrome Treatment Market

• 8.1. Asia-Pacific Cytokine Release Syndrome Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cytokine Release Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Cytokine Release Syndrome Treatment Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Cytokine Release Syndrome Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cytokine Release Syndrome Treatment Market

• 9.1. China Cytokine Release Syndrome Treatment Market Overview
• 9.2. China Cytokine Release Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Cytokine Release Syndrome Treatment Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Cytokine Release Syndrome Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cytokine Release Syndrome Treatment Market

• 10.1. India Cytokine Release Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Cytokine Release Syndrome Treatment Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Cytokine Release Syndrome Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cytokine Release Syndrome Treatment Market

• 11.1. Japan Cytokine Release Syndrome Treatment Market Overview
• 11.2. Japan Cytokine Release Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Cytokine Release Syndrome Treatment Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Cytokine Release Syndrome Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cytokine Release Syndrome Treatment Market

• 12.1. Australia Cytokine Release Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Cytokine Release Syndrome Treatment Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Cytokine Release Syndrome Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cytokine Release Syndrome Treatment Market

• 13.1. Indonesia Cytokine Release Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Cytokine Release Syndrome Treatment Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Cytokine Release Syndrome Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cytokine Release Syndrome Treatment Market

• 14.1. South Korea Cytokine Release Syndrome Treatment Market Overview
• 14.2. South Korea Cytokine Release Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Cytokine Release Syndrome Treatment Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Cytokine Release Syndrome Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cytokine Release Syndrome Treatment Market

• 15.1. Western Europe Cytokine Release Syndrome Treatment Market Overview
• 15.2. Western Europe Cytokine Release Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Cytokine Release Syndrome Treatment Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Cytokine Release Syndrome Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cytokine Release Syndrome Treatment Market

• 16.1. UK Cytokine Release Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Cytokine Release Syndrome Treatment Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Cytokine Release Syndrome Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cytokine Release Syndrome Treatment Market

• 17.1. Germany Cytokine Release Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Cytokine Release Syndrome Treatment Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Cytokine Release Syndrome Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cytokine Release Syndrome Treatment Market

• 18.1. France Cytokine Release Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Cytokine Release Syndrome Treatment Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Cytokine Release Syndrome Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cytokine Release Syndrome Treatment Market

• 19.1. Italy Cytokine Release Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Cytokine Release Syndrome Treatment Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Cytokine Release Syndrome Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cytokine Release Syndrome Treatment Market

• 20.1. Spain Cytokine Release Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Cytokine Release Syndrome Treatment Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Cytokine Release Syndrome Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cytokine Release Syndrome Treatment Market

• 21.1. Eastern Europe Cytokine Release Syndrome Treatment Market Overview
• 21.2. Eastern Europe Cytokine Release Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Cytokine Release Syndrome Treatment Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Cytokine Release Syndrome Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cytokine Release Syndrome Treatment Market

• 22.1. Russia Cytokine Release Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Cytokine Release Syndrome Treatment Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Cytokine Release Syndrome Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cytokine Release Syndrome Treatment Market

• 23.1. North America Cytokine Release Syndrome Treatment Market Overview
• 23.2. North America Cytokine Release Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Cytokine Release Syndrome Treatment Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Cytokine Release Syndrome Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cytokine Release Syndrome Treatment Market

• 24.1. USA Cytokine Release Syndrome Treatment Market Overview
• 24.2. USA Cytokine Release Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Cytokine Release Syndrome Treatment Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Cytokine Release Syndrome Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cytokine Release Syndrome Treatment Market

• 25.1. Canada Cytokine Release Syndrome Treatment Market Overview
• 25.2. Canada Cytokine Release Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Cytokine Release Syndrome Treatment Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Cytokine Release Syndrome Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cytokine Release Syndrome Treatment Market

• 26.1. South America Cytokine Release Syndrome Treatment Market Overview
• 26.2. South America Cytokine Release Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Cytokine Release Syndrome Treatment Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Cytokine Release Syndrome Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cytokine Release Syndrome Treatment Market

• 27.1. Brazil Cytokine Release Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Cytokine Release Syndrome Treatment Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Cytokine Release Syndrome Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cytokine Release Syndrome Treatment Market

• 28.1. Middle East Cytokine Release Syndrome Treatment Market Overview
• 28.2. Middle East Cytokine Release Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Cytokine Release Syndrome Treatment Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Cytokine Release Syndrome Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cytokine Release Syndrome Treatment Market

• 29.1. Africa Cytokine Release Syndrome Treatment Market Overview
• 29.2. Africa Cytokine Release Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Cytokine Release Syndrome Treatment Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Cytokine Release Syndrome Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cytokine Release Syndrome Treatment Market Competitive Landscape And Company Profiles

• 30.1. Cytokine Release Syndrome Treatment Market Competitive Landscape
• 30.2. Cytokine Release Syndrome Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Cytokine Release Syndrome Treatment Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Sanofi S.A.
• 31.3. Thermo Fisher Scientific Inc.
• 31.4. Novartis AG
• 31.5. GlaxoSmithKline plc
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Eli Lilly and Company
• 31.8. Gilead Sciences Inc.
• 31.9. Amgen Inc.
• 31.10. Regeneron Pharmaceuticals Inc.
• 31.11. Chugai Pharmaceutical Co. Ltd.
• 31.12. Incyte Corporation
• 31.13. Swedish Orphan Biovitrum AB (publ)
• 31.14. Bio-Techne Corporation
• 31.15. GenScript Biotech Corporation

32. Global Cytokine Release Syndrome Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cytokine Release Syndrome Treatment Market

34. Recent Developments In The Cytokine Release Syndrome Treatment Market

35. Cytokine Release Syndrome Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Cytokine Release Syndrome Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Cytokine Release Syndrome Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Cytokine Release Syndrome Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250423_r33472_Cytokine_Release_Syndrome_Treatment_GMR_2025